Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

Poordad, 2011, Boceprevir for untreated chronic HCV genotype 1 infection, N Engl J Med, 364, 1195, 10.1056/NEJMoa1010494 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, N Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Jacobson, 2011, Telaprevir for previously untreated chronic hepatitis C virus infection, N Engl J Med, 364, 2405, 10.1056/NEJMoa1012912 Zeuzem, 2011, Telaprevir for retreatment of HCV infection, N Engl J Med, 364, 2417, 10.1056/NEJMoa1013086 Bruno, 2009, Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study, Am J Gastroenterol, 104, 1147, 10.1038/ajg.2009.31 Dienstag, 2011, A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C, Hepatology, 54, 396, 10.1002/hep.24370 N’Kontchou, 2006, Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis, Clin Gastroenterol Hepatol, 4, 1062, 10.1016/j.cgh.2006.05.013 Sangiovanni, 2006, The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients, Hepatology, 43, 1303, 10.1002/hep.21176 Bruno, 2007, Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study, Hepatology, 45, 579, 10.1002/hep.21492 Mallet, 2008, Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C, Ann Intern Med, 149, 399, 10.7326/0003-4819-149-6-200809160-00006 Morgan, 2010, Outcome of sustained virological responders with histologically advanced chronic hepatitis C, Hepatology, 52, 833, 10.1002/hep.23744 van der Meer, 2012, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis, JAMA, 308, 2584, 10.1001/jama.2012.144878 Bruno, 2010, Efficacy and safety of peginterferon alfa-2a (40KDa) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis, Hepatology, 51, 388, 10.1002/hep.23340 Marrache, 2005, Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis, J Viral Hepatitis, 12, 421, 10.1111/j.1365-2893.2005.00609.x Carrion, 2009, Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study, J Hepatol, 50, 719, 10.1016/j.jhep.2008.11.015 Pol, 2011, Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study, Hepatology, 54, 374A Fontaine, 2007, Guidelines for the diagnosis of uncomplicated cirrhosis, Gastroenterol Clin Biol, 31, 504, 10.1016/S0399-8320(07)89420-6 Cacoub, 2012, Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals, J Hepatol, 56, 455, 10.1016/j.jhep.2011.08.006 Chevaliez, 2007, Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, 46, 22, 10.1002/hep.21656 Chevaliez, 2009, Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification, J Clin Microbiol, 47, 1726, 10.1128/JCM.01300-08 Bruno, 2013, Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis, J Hepatol, 58, 479, 10.1016/j.jhep.2012.11.020 Iacobellis, 2007, Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study, J Hepatol, 46, 206, 10.1016/j.jhep.2006.08.020 Di Bisceglie, 2008, Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon, N Engl J Med, 359, 2429, 10.1056/NEJMoa0707615 Bruix, 2011, Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C, Gastroenterology, 140, 1990, 10.1053/j.gastro.2011.03.010 Sarrazin, 2012, Antiviral strategies in hepatitis C virus infection, J Hepatol, 56, S88, 10.1016/S0168-8278(12)60010-5